Thomas Loughran

Trials

Studies that name Thomas Loughran as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:47 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT00360776 · Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia

  National Cancer Institute (NCI) · terminated · Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 01:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 18 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
  U01CA062502 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI AFSHIN DOWLATI · fiscal years 1994 to 2013
  Named on NCT00360776